Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04953533
Other study ID # 2020C03044
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 6, 2021
Est. completion date December 31, 2023

Study information

Verified date January 2021
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Huaxiang Wu, PHD
Phone 13757118395
Email wuhx8855@sina.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate differences in specific SNPs and intestinal microflora between patients with gout and hyperuricemia and healthy controls.


Description:

1. To evaluate differences in specific SNPs and intestinal microflora between patients with gout and hyperuricemia and healthy controls. 2. to measure the level of uric acid in feces.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date December 31, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 25 Years to 60 Years
Eligibility gout Inclusion Criteria: 1. age:year of 25~60; 2. Be consistent with the 2015 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) gout diagnostic criteria ,and serum uric acid >420 µmol/L; 3. The patient are willing to take part in our study. Exclusion Criteria: 1. abronia, surgery, postoperative, dehydration within 2 weeks, acute or chronic infectious diseases, severe trauma, malnutrition, diabetes, malignant tumors; 2. diagnosed as cardiovascular and cerebrovascular diseases within 3 months; 3. heart failure (New York Heart Academy,grade IV); 4. hepatic insufficiency ( Alanine transaminase or Aspartate aminotransferase =3×upper limit); 5. chronic kidney disease or abnormal renal function( serum creatinine =1.5×upper limit); 6. excessive drinking; 7. The investigators considered the patients unsuitable for inclusion in this study. hyperuricemia: Inclusion Criteria: 1. age:year of 25~60; 2. A medical record in our hospital showed that the person is healthy, without key disease; 3. serum uric acid >420µmol/L without gout flares. Exclusion Criteria:Same as the group of gout. healthy controls: Inclusion Criteria: age:year of 25~60; A medical record in our hospital showed that the person is healthy, without key disease; serum uric acid =420µmol/L. Exclusion Criteria:Same as the group of gout.

Study Design


Intervention

Other:
no intervention


Locations

Country Name City State
China the second affliated hospital of Zhejiang university School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the difference of the specific Single Nucleotide Polymorphisms(SNPs) We will test the specific SNPs that we have selected before, such as rs670, rs671, rs1014290 and so on. The SNPs will be tested by Taqman SNP assay and verified by sequencing. 2021.1.6--2021.12.31
Primary intestinal flora Feces will be collected in gout, hyperuricemia patients and healthy subjects. ofIntestinal flora will be tested and analysed. The detailed measurement is as follows: Firstly, the DNA of feces will be extracted according to the protocol of Fecal DNA Extraction Kit. Then, the concentration and purity of fecal DNA will be tested by spectrophotometer. Sequencing of the V3-V4 region of the 16S ribosomal RNA gene, building a library and then sequencing the qualified libraries by Illumina Platform(MiSeq). Using the QIIME?UCLUST?SILVA and Kyoto Encyclopedia of Genes and Genomes(KEGG) database to comparison and screen the intestinal bacterial with statistical significance. Operational taxonomic unit (OTU), a-diversity, ß-diversity indices and so on of the fecal microbiota will be analyzed in patients with gout and hyperuricemia and normal control. 2021.1.6--2022.12.31
Primary feces uric acid level Feces uric acid level will be tested by uric acid assay kit and we will analyze the differences of feces uric acid level in gout, hyperuricemia patients and healthy subjects. 2021.1.6--2.22.12.31
Secondary the incidence of gout in patients with hyperuricemia follow-up the patients with hyperuricemia for at least one year, calculate the incidence of hyperuricemia patients develop to gout. 2021.12.31--2023.12.31
See also
  Status Clinical Trial Phase
Completed NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Phase 1
Not yet recruiting NCT06187519 - UR+AIMS Gout Wearable Skin Uric Acid Monitor Study N/A
Completed NCT03635957 - Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Phase 4
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT03015948 - A Single Dose Study of SHR4640 in Healthy Male Volunteers Phase 1
Completed NCT02855437 - Novel Methods for Ascertainment of Gout Flares -A Pilot Study N/A
Active, not recruiting NCT02702375 - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases N/A
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00985127 - Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT03291782 - D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers Phase 1
Recruiting NCT03388515 - A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Enrolling by invitation NCT03336203 - The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Phase 4
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Recruiting NCT04047394 - A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers Phase 1
Not yet recruiting NCT05507723 - Tight Control of Gouty Arthritis Compared to Usual Care N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2